DelveInsight's, "Severe Asthma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Severe Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Severe Asthma Pipeline. Dive into DelveInsight's comprehensive report today! @ Severe Asthma Pipeline Outlook
Key Takeaways from the Severe Asthma Pipeline Report*
Stay ahead with the most recent pipeline outlook for Severe Asthma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Severe Asthma Approved Drugs
Severe Asthma Emerging Drugs*GSK3511294:
GSK 3511294, also known as depemokimab, is a long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody, being developed by
BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion's collaboration partner - CTTQ, a
Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody administered subcutaneously via syringe or autoinjector. It is currently indicated for several conditions: as an add-on maintenance treatment for adult and pediatric patients aged six years and older with severe asthma characterized by an eosinophilic phenotype; as an add-on maintenance treatment for adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps; for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis; and for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome of at least six months' duration without an identifiable non-hematologic secondary cause. Currently the drug is in Phase I stage of its clinical trial for the treatment of severe asthma.
Explore groundbreaking therapies and clinical trials in the Severe Asthma Pipeline. Access DelveInsight's detailed report now! @ Severe Asthma Treatment Drugs
Severe Asthma Companies
Kinaset Therapeutics,
Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration*
Severe Asthma Products have been categorized under various Molecule types such as*Recombinant fusion proteins *Small molecule *Monoclonal antibody *Peptide *Polymer *Gene therapy
Unveil the future of Severe Asthma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Severe Asthma Market Drivers and Barriers
Scope of the Severe Asthma Pipeline Report*Coverage- Global *Severe Asthma Companies- Kinaset Therapeutics,
Get the latest on Severe Asthma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Severe Asthma Companies, Key Products and Unmet Needs
Table of Content*Introduction *Executive Summary *Severe Asthma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Severe Asthma- DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *GSK3511294:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source